| Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index JR Junutula, H Raab, S Clark, S Bhakta, DD Leipold, S Weir, Y Chen, ... Nature biotechnology 26 (8), 925-932, 2008 | 1449 | 2008 |
| Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen Y Chen, C Wiesmann, G Fuh, B Li, HW Christinger, P McKay, AM de Vos, ... Journal of molecular biology 293 (4), 865-881, 1999 | 1126 | 1999 |
| Development of ranibizumab, an anti–vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration N Ferrara, L Damico, N Shams, H Lowman, R Kim Retina 26 (8), 859-870, 2006 | 1076 | 2006 |
| Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants LJ Garrard, DJ Henner, S Bass, R Greene, HB Lowman, JA Wells, ... US Patent 5,750,373, 1998 | 992 | 1998 |
| FIZZ1, a novel cysteine‐rich secreted protein associated with pulmonary inflammation, defines a new gene family IN Holcomb, RC Kabakoff, B Chan, TW Baker, A Gurney, W Henzel, ... The EMBO journal, 2000 | 964 | 2000 |
| Cysteine engineered antibodies and conjugates CW Eigenbrot, JR Junutula, H Lowman, HE Raab, R Vandlen US Patent 7,521,541, 2009 | 797 | 2009 |
| Monovalent phage display LJ Garrard, DJ Henner, S Bass, R Greene, HB Lowman, JA Wells, ... US Patent 5,821,047, 1998 | 709 | 1998 |
| Selecting high-affinity binding proteins by monovalent phage display HB Lowman, SH Bass, N Simpson, JA Wells Biochemistry 30 (45), 10832-10838, 1991 | 643 | 1991 |
| [21] Phage display for selection of novel binding peptides SS Sidhu, HB Lowman, BC Cunningham, JA Wells Methods in enzymology 328, 333-IN5, 2000 | 639 | 2000 |
| VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface YA Muller, Y Chen, HW Christinger, B Li, BC Cunningham, HB Lowman, ... Structure 6 (9), 1153-1167, 1998 | 397 | 1998 |
| Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates YA Yeung, MK Leabman, JS Marvin, J Qiu, CW Adams, S Lien, ... The Journal of Immunology 182 (12), 7663-7671, 2009 | 355 | 2009 |
| Bacteriophage display and discovery of peptide leads for drug development HB Lowman Annual review of biophysics and biomolecular structure 26 (1), 401-424, 1997 | 354 | 1997 |
| Affinity maturation of human growth hormone by monovalent phage display HB Lowman, JA Wells Journal of molecular biology 234 (3), 564-578, 1993 | 329 | 1993 |
| Therapeutic peptides S Lien, HB Lowman Trends in biotechnology 21 (12), 556-562, 2003 | 295 | 2003 |
| Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index LR Desnoyers, O Vasiljeva, JH Richardson, A Yang, EEM Menendez, ... Science translational medicine 5 (207), 207ra144-207ra144, 2013 | 289 | 2013 |
| Interaction between bevacizumab and murine VEGF-A: a reassessment L Yu, X Wu, Z Cheng, CV Lee, J LeCouter, C Campa, G Fuh, H Lowman, ... Investigative ophthalmology & visual science 49 (2), 522-527, 2008 | 284 | 2008 |
| Anti-VEGF antibodies M Baca, JA Wells, LG Presta, HB Lowman, YM Chen US Patent 7,169,901, 2007 | 259 | 2007 |
| Human growth hormone variants BC Cunningham, HB Lowman, JA Wells, RG Clark, K Olson, GG Fuh US Patent 5,849,535, 1998 | 234 | 1998 |
| Structure of a CXC chemokine-receptor fragment in complex with interleukin-8 NJ Skelton, C Quan, D Reilly, H Lowman Structure 7 (2), 157-168, 1999 | 232 | 1999 |
| Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs JR Junutula, S Bhakta, H Raab, KE Ervin, C Eigenbrot, R Vandlen, ... Journal of immunological methods 332 (1-2), 41-52, 2008 | 221 | 2008 |
